All In Biotech

Drug Trial Radar · NCT00689338

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations

Last checked: Nov 20, 2026Latest source record: May 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

216

Actual

Start

Jul 2008

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients.

Conditions

  • Invasive Candidiasis

Interventions

  • AnidulafunginDrug

    Anidulafungin Intravenous Administration

  • FluconazoleDrug

    Oral Administration of Fluconazole

  • VoriconazoleDrug

    Oral Administration of Voriconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Global Treatment Response Success at End of TreatmentTime frame: End of Treatment (Day 14 to Day 56)

Locations

61 sites in 19 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Vienna, Austria

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Brussels, Belgium

  • Pfizer Investigational Site

    Ghent, Belgium

  • Pfizer Investigational Site

    Leuven, Belgium

  • Pfizer Investigational Site

    Liège, Belgium

  • Pfizer Investigational Site

    Yvoir, Belgium

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Hamilton, Ontario, Canada

  • Pfizer Investigational Site

    Québec, Quebec, Canada

  • Pfizer Investigational Site

    Brno, Czechia

  • Pfizer Investigational Site

    Ostrava, Czechia

  • Pfizer Investigational Site

    Prague, Czechia

  • Pfizer Investigational Site

    Koebenhavn OE, Denmark

  • Pfizer Investigational Site

    Odense C, Denmark

  • Pfizer Investigational Site

    Villejuif, France

  • Pfizer Investigational Site

    Amiens, France, France

  • Pfizer Investigational Site

    Bordeaux, France, France

  • Pfizer Investigational Site

    Clichy, France, France

  • Pfizer Investigational Site

    Lyon, France, France

  • Pfizer Investigational Site

    Marseille, France, France

  • Pfizer Investigational Site

    Montpellier, France, France

  • Pfizer Investigational Site

    Paris, France, France

  • Pfizer Investigational Site

    Berlin, Germany

  • Pfizer Investigational Site

    Freiburg im Breisgau, Germany

  • Pfizer Investigational Site

    Wuppertal, Germany

  • Pfizer Investigational Site

    Kifissia, Athens, Greece

  • Pfizer Investigational Site

    Haidari, Attica, Greece

  • Pfizer Investigational Site

    Budapest, Hungary

  • Pfizer Investigational Site

    Budapest, Hungary

  • Pfizer Investigational Site

    Pisa, Italy

  • Pfizer Investigational Site

    Roma, Italy

  • Pfizer Investigational Site

    Roma, Italy

  • Pfizer Investigational Site

    Torino, Italy

  • Pfizer Investigational Site

    Udine, Italy

  • Pfizer Investigational Site

    Ede, Netherlands

  • Pfizer Investigational Site

    Rotterdam, Netherlands

  • Pfizer Investigational Site

    Krakow, Poland

  • Pfizer Investigational Site

    Lodz, Poland

  • Pfizer Investigational Site

    Coimbra, Portugal

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.